Semaglutide — the medication that proved GLP-1 weight loss to the world, with the deepest evidence file in the class including cardiovascular outcome benefits. Full supervised program with genuine pens at Peace Clinic.
Wegovy is once-weekly semaglutide at obesity-treatment doses: quieting appetite and food noise through the GLP-1 pathway, averaging ~15% body-weight loss in landmark trials.
Its distinguishing asset is evidence depth — including the SELECT trial's demonstrated reduction in cardiovascular events for patients with heart-risk profiles, unique in the class.
Weekly tiny-needle self-injection; simple after supervised teaching.
Appetite settles in weeks 1–2; progressive loss through titration months.
~15% average at 68 weeks in trials; taper plan protects results.
Monthly cost by dose stage, quoted transparently with labs included. Counterfeit online pens are common — genuine supply matters.
Weight-management medication is prescribed and monitored by a doctor. It does not suit everyone and always needs a health assessment first, so it is not something to choose from a comparison table.
The doctor consultation is free — message @peaceclinicth on LINE to book an assessment.
If cardiovascular history or risk matters in your profile, Wegovy's outcome data is unmatched. For maximum average loss, Mounjaro edges ahead. Doctor consultation decides properly.
Same molecule; Wegovy is the obesity-dose, obesity-indicated product. Dosing and titration differ.
With our taper-plus-habits exit strategy, maintenance is realistic; abrupt unplanned stopping commonly rebounds.